Variable coding sequence protein A1 as a marker for erectile dysfunction

Yuehong Tong, Moses T. Tar, Felix Davelman, George Christ, Arnold Melman, Kelvin Davies

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

OBJECTIVE: To investigate whether variable coding sequence protein A1 (Vcsa1) is down-regulated in rat models of diabetes and ageing, and to investigate the role of Vcsa1 in erectile function, as Vcsa1 is the most down-regulated gene in the corpora of a rat model of neurogenic erectile dysfunction (ED). MATERIALS AND METHODS: Quantitative reverse-transcriptase polymerase-chain reaction was used to determine Vcsa1 expression in the corpora of rats in three models of ED, i.e. streptozotocin-induced diabetes, retired breeder (old), and neurogenic (bilaterally ligated cavernosal nerves), and in control rats. To confirm a physiological role of Vcsa1 in erectile function, we carried out gene transfer studies using a plasmid in which Vcsa1 was expressed from a cytomegalovirus promoter (pVAX-Vcsa1). This plasmid was injected intracorporally into old rats, and the effect on physiology of corporal tissue was analysed by intracorporal/blood pressure (ICP/BP) measurement and histological analysis, and compared with the effects of a positive control plasmid (pVAX-hSlo, which we previously reported to restore erectile function in diabetic and ageing rats) and a negative control plasmid (pVAX). RESULTS: In each rat model of ED there was a significant down-regulation of the Vcsa1 transcript of at least 10-fold in corporal tissue. Remarkably, intracorporal injection with 80 μg pVAX-Vcsa1 caused priapism, as indicated by visible prolonged erection, histological appearance, and elevated resting ICP/BP. Lower doses of pVAX-Vcsa1 (5 and 25 μg) increased ICP/BP over that in untreated controls. CONCLUSION: These results show that Vcsa1 has a role in erectile function and might be a molecular marker for organic ED. The role of Vcsa1 in erectile function suggests that it could represent a novel therapeutic target for treating ED.

Original languageEnglish (US)
Pages (from-to)396-401
Number of pages6
JournalBJU International
Volume98
Issue number2
DOIs
StatePublished - Aug 2006

Fingerprint

Erectile Dysfunction
Proteins
Plasmids
Blood Pressure
Priapism
Experimental Diabetes Mellitus
Reverse Transcriptase Polymerase Chain Reaction
Cytomegalovirus
Genes
Down-Regulation

Keywords

  • Ageing
  • Diabetes
  • Erectile dysfunction
  • Gene transfer
  • Priapism
  • SMR-1
  • Vcsa1

ASJC Scopus subject areas

  • Urology

Cite this

Variable coding sequence protein A1 as a marker for erectile dysfunction. / Tong, Yuehong; Tar, Moses T.; Davelman, Felix; Christ, George; Melman, Arnold; Davies, Kelvin.

In: BJU International, Vol. 98, No. 2, 08.2006, p. 396-401.

Research output: Contribution to journalArticle

Tong, Yuehong ; Tar, Moses T. ; Davelman, Felix ; Christ, George ; Melman, Arnold ; Davies, Kelvin. / Variable coding sequence protein A1 as a marker for erectile dysfunction. In: BJU International. 2006 ; Vol. 98, No. 2. pp. 396-401.
@article{def02196a2134f79a98e7541515ee1e6,
title = "Variable coding sequence protein A1 as a marker for erectile dysfunction",
abstract = "OBJECTIVE: To investigate whether variable coding sequence protein A1 (Vcsa1) is down-regulated in rat models of diabetes and ageing, and to investigate the role of Vcsa1 in erectile function, as Vcsa1 is the most down-regulated gene in the corpora of a rat model of neurogenic erectile dysfunction (ED). MATERIALS AND METHODS: Quantitative reverse-transcriptase polymerase-chain reaction was used to determine Vcsa1 expression in the corpora of rats in three models of ED, i.e. streptozotocin-induced diabetes, retired breeder (old), and neurogenic (bilaterally ligated cavernosal nerves), and in control rats. To confirm a physiological role of Vcsa1 in erectile function, we carried out gene transfer studies using a plasmid in which Vcsa1 was expressed from a cytomegalovirus promoter (pVAX-Vcsa1). This plasmid was injected intracorporally into old rats, and the effect on physiology of corporal tissue was analysed by intracorporal/blood pressure (ICP/BP) measurement and histological analysis, and compared with the effects of a positive control plasmid (pVAX-hSlo, which we previously reported to restore erectile function in diabetic and ageing rats) and a negative control plasmid (pVAX). RESULTS: In each rat model of ED there was a significant down-regulation of the Vcsa1 transcript of at least 10-fold in corporal tissue. Remarkably, intracorporal injection with 80 μg pVAX-Vcsa1 caused priapism, as indicated by visible prolonged erection, histological appearance, and elevated resting ICP/BP. Lower doses of pVAX-Vcsa1 (5 and 25 μg) increased ICP/BP over that in untreated controls. CONCLUSION: These results show that Vcsa1 has a role in erectile function and might be a molecular marker for organic ED. The role of Vcsa1 in erectile function suggests that it could represent a novel therapeutic target for treating ED.",
keywords = "Ageing, Diabetes, Erectile dysfunction, Gene transfer, Priapism, SMR-1, Vcsa1",
author = "Yuehong Tong and Tar, {Moses T.} and Felix Davelman and George Christ and Arnold Melman and Kelvin Davies",
year = "2006",
month = "8",
doi = "10.1111/j.1464-410X.2006.06247.x",
language = "English (US)",
volume = "98",
pages = "396--401",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Variable coding sequence protein A1 as a marker for erectile dysfunction

AU - Tong, Yuehong

AU - Tar, Moses T.

AU - Davelman, Felix

AU - Christ, George

AU - Melman, Arnold

AU - Davies, Kelvin

PY - 2006/8

Y1 - 2006/8

N2 - OBJECTIVE: To investigate whether variable coding sequence protein A1 (Vcsa1) is down-regulated in rat models of diabetes and ageing, and to investigate the role of Vcsa1 in erectile function, as Vcsa1 is the most down-regulated gene in the corpora of a rat model of neurogenic erectile dysfunction (ED). MATERIALS AND METHODS: Quantitative reverse-transcriptase polymerase-chain reaction was used to determine Vcsa1 expression in the corpora of rats in three models of ED, i.e. streptozotocin-induced diabetes, retired breeder (old), and neurogenic (bilaterally ligated cavernosal nerves), and in control rats. To confirm a physiological role of Vcsa1 in erectile function, we carried out gene transfer studies using a plasmid in which Vcsa1 was expressed from a cytomegalovirus promoter (pVAX-Vcsa1). This plasmid was injected intracorporally into old rats, and the effect on physiology of corporal tissue was analysed by intracorporal/blood pressure (ICP/BP) measurement and histological analysis, and compared with the effects of a positive control plasmid (pVAX-hSlo, which we previously reported to restore erectile function in diabetic and ageing rats) and a negative control plasmid (pVAX). RESULTS: In each rat model of ED there was a significant down-regulation of the Vcsa1 transcript of at least 10-fold in corporal tissue. Remarkably, intracorporal injection with 80 μg pVAX-Vcsa1 caused priapism, as indicated by visible prolonged erection, histological appearance, and elevated resting ICP/BP. Lower doses of pVAX-Vcsa1 (5 and 25 μg) increased ICP/BP over that in untreated controls. CONCLUSION: These results show that Vcsa1 has a role in erectile function and might be a molecular marker for organic ED. The role of Vcsa1 in erectile function suggests that it could represent a novel therapeutic target for treating ED.

AB - OBJECTIVE: To investigate whether variable coding sequence protein A1 (Vcsa1) is down-regulated in rat models of diabetes and ageing, and to investigate the role of Vcsa1 in erectile function, as Vcsa1 is the most down-regulated gene in the corpora of a rat model of neurogenic erectile dysfunction (ED). MATERIALS AND METHODS: Quantitative reverse-transcriptase polymerase-chain reaction was used to determine Vcsa1 expression in the corpora of rats in three models of ED, i.e. streptozotocin-induced diabetes, retired breeder (old), and neurogenic (bilaterally ligated cavernosal nerves), and in control rats. To confirm a physiological role of Vcsa1 in erectile function, we carried out gene transfer studies using a plasmid in which Vcsa1 was expressed from a cytomegalovirus promoter (pVAX-Vcsa1). This plasmid was injected intracorporally into old rats, and the effect on physiology of corporal tissue was analysed by intracorporal/blood pressure (ICP/BP) measurement and histological analysis, and compared with the effects of a positive control plasmid (pVAX-hSlo, which we previously reported to restore erectile function in diabetic and ageing rats) and a negative control plasmid (pVAX). RESULTS: In each rat model of ED there was a significant down-regulation of the Vcsa1 transcript of at least 10-fold in corporal tissue. Remarkably, intracorporal injection with 80 μg pVAX-Vcsa1 caused priapism, as indicated by visible prolonged erection, histological appearance, and elevated resting ICP/BP. Lower doses of pVAX-Vcsa1 (5 and 25 μg) increased ICP/BP over that in untreated controls. CONCLUSION: These results show that Vcsa1 has a role in erectile function and might be a molecular marker for organic ED. The role of Vcsa1 in erectile function suggests that it could represent a novel therapeutic target for treating ED.

KW - Ageing

KW - Diabetes

KW - Erectile dysfunction

KW - Gene transfer

KW - Priapism

KW - SMR-1

KW - Vcsa1

UR - http://www.scopus.com/inward/record.url?scp=33745726513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745726513&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2006.06247.x

DO - 10.1111/j.1464-410X.2006.06247.x

M3 - Article

C2 - 16879685

AN - SCOPUS:33745726513

VL - 98

SP - 396

EP - 401

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -